Health1 day ago
Mesoblast Achieves 66% Revenue Growth in Q2 Driven by Ryoncil Sales
Mesoblast, an Australian biotechnology company, reported a remarkable revenue increase of 66% for the second quarter of 2023, primarily driven by strong sales of its flagship...
